期刊文献+

卡培他滨治疗晚期肾癌32例临床观察 被引量:2

Clinical observation of capecitabine in treating 32 patients with metastatic renal cancer
暂未订购
导出
摘要 目的:观察卡培他滨治疗晚期肾癌的疗效及不良反应。方法:经影像学诊断的晚期肾癌32例,使用卡培他滨2000mg/m2,分2次口服,d1-14,每3周1个周期,至少用4周期以上评价疗效。结果:32例均可评价疗效,CR 0例,PR 7例,总有效率21.9%(7/32)。主要不良反应为恶心、呕吐、手足综合征、骨髓抑制及腹泻,无化疗相关死亡。结论:卡培他滨治疗晚期肾癌有一定疗效,不良反应可以耐受,值得深入研究。 Objective:To evaluate the clinical effect and toxicity of capecitabine in the treatment of metastatic renal cancer.Methods:All 32 patients with metastatic renal cancer diagnosed by imageology were treated with capecitabine 2000mg/m^2 twice daily orally on day 1-14.The regimen was repeated every 21 days at least four cycles.Results:Of 32 patients complete remission(CR) was observed in 0 case and PR in 7 cases,the total response rate was 21.9%(7/32).The main side effects were myelosuppression,diarrhea,hand-foot syndrome and nausea /vomiting.There were no any death events during treatment.Conclusion:Capecitabine in the treatment of metastatic renal cancer is effective and tolerable.
出处 《现代肿瘤医学》 CAS 2012年第11期2357-2358,共2页 Journal of Modern Oncology
关键词 肾癌 卡培他滨 治疗 renal cancer capecitabine treatment
  • 相关文献

参考文献10

  • 1孙燕;石远凯.泌尿系统肿瘤[J]临床肿瘤内科,2007648-653.
  • 2Ellerhorst JA,Sella A,Amato R J. Phase Ⅱ trial of 5-fluorouracil,interferon-alpha and continuous infusion interlerkin-2 for patients with metastatic renal cell carcinoma[J].Cancer,1997.2128-2132.
  • 3Motzer RJ,Bahnson RR,Carducci MA. National comprehensive cancer net clinical practice guidelines in oncology[J].Kidney Cancer,2003.1-16.
  • 4Ishikawa T,Sekiguchi F,Fukase Y. Antitumor activities of a novel fluoropyrimidine,N4-pentyloxycarbonyl-5 '-deoxy-5fluorocyt idine (capecitabine)[J].Biological and Pharmaceutical Bulletin,1998.713-717.
  • 5Overmann K,Buer J,Hoffmann R. Capecitabine in the treatmeat of metastatic renal cell carcinoma[J].British Journal of Cancer,2000.583-587.
  • 6王少华;杜冠华;孙玉安.泌尿系统恶性肿瘤的合理用药[J]肿瘤合理用药,2009(01):715-721.
  • 7孙曾一;胥彬;应江山.泌尿生殖系统肿瘤的化疗[J]肿瘤化疗进展,2008(05):159-162.
  • 8武晓楠,赵赟博,伍建宇,李琳,程刚,周美珍.卡培他滨单药治疗老年晚期胃癌临床分析[J].现代肿瘤医学,2010,18(2):339-341. 被引量:23
  • 9袁彬,吴敏慧,杨琪,周璐,蒋喆,施常备.Xelox方案治疗老年胃肠道肿瘤的临床观察[J].现代肿瘤医学,2009,17(2):291-292. 被引量:7
  • 10于丁;于金明;上野秀树.转移性肾癌内科治疗进展[J]中国肿瘤内科治疗进展,2011(01):219-222.

二级参考文献17

共引文献28

同被引文献50

  • 1石明,韩平,曹贵华,魏强,杨宇如.肾癌术后应用α-干扰素的疗效分析[J].华西医学,2006,21(2):288-289. 被引量:6
  • 2那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版)[M].北京:人民卫生出版社,2014:528.
  • 3International Agency for research on cancer: GLOBOCAN 2012: estimated cancer indence, mortality and prevalence wordwiade in 2012[DB/MTJ. http s./Zglobocan. iarc. fr/Pages/fact_sheets_population. aspx,2015 - 3 -1.
  • 4National Cacer Instute , SEER cancer statistics 2014 [DB/MT]. http://seer. cancer. grv/statfacts/htmVkidrp. html,2015 -3-1.
  • 5Ferlay J , Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006 [J]. Annals of oncology , 2007,18 (3) ;581 - 592.
  • 6Gupta S, Spiess PE. The prospects of pazopanib in advance reanl cell carcinoma [J] . Ther Adv Urol ,2013,5 :223 - 232.
  • 7Bukowski RM. Natural history and theraph of metastatic reanl cell carcinoma: The role of interleukin - 2 [J] . Cancer, 1997 ,80 : 1198 -1220.
  • 8Gunduz S, Mutiu H, Uysal M, et al. Prognostic value of hematologic parameters in patients metastatic reanl cell carcinoma using tyrosine kinase inhibitors[J]. Asian Pac J Cancer Prev,2014,15(8): 3801 -3804.
  • 9Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa - 2b compared with interferon alfa - 2b alone for metastatic reanl cell carcinoma[J]. N Engl J Med,2001, 345(23) :1655 -1659.
  • 10Mikisch GH, Garin A. Van PH, et al. Radical nephrectomy puls interferon alfa alone in metastatic reanl cell carcinoma: a randomized trial] L]. Lancet,2011 ,358 :966 -970.

引证文献2

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部